Expand your understanding of acute myeloid leukemia (AML) targeted therapy options and how cytogenetics influences treatment decisions with this webcast of our satellite symposium at the 22nd Congress of the European Hematology Association in Madrid, Spain. Initial discussion will focus on AML subgroups classification. From there, options in initial therapy and relapsed or refractory disease will be featured. Finally, new targeted options will be examined in detail.
This engaging activity will provide a foundation for further exploration of new treatment options in newly-diagnosed and relapsed/refractory disease.
Examining genetics and genomics in AML in 2017
Elli Papaemmauil, PhD
Personalizing initial therapy in AML
Francesco Lo Coco, MD
What’s on the horizon for relapsed/refractory AML?
Lisa Pleyer, MD
A deeper dive into AML subgroups
Miguel Sanz, MD
Miguel Sanz, MD
Miguel Sanz, MDValencia University Medical School
University Hospital La Fe
Francesco Lo Coco, MDUniversity Tor Vergata
Lisa Pleyer, MDSalzburg Cancer Research Institute
Elli Papaemmanuil, PhDMemorial Sloan Kettering Cancer Center
New York, New York, United States
The proposed educational activity is specifically designed to meet the needs of hematologists, oncologists, pathologists, and other healthcare professionals involved in the treatment of patients with AML.
The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.
After successful completion of this educational activity, participants should be able to:
- Compare current AML classification systems and the role that cytogenetics plays in them
- Describe molecularly-defined subtypes of AML
- Evaluate current initial therapeutic strategies in newly-diagnosed AML based on patient and disease characteristics
- Identify novel agents being investigated in relapsed/refractory AML
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by grants from Celgene, Helsinn Healthcare SA, and Novartis Oncology.
July 21, 2017
July 21, 2018